BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34946727)

  • 21. MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
    Watson AF; Liu J; Bennaceur K; Drummond CJ; Endicott JA; Golding BT; Griffin RJ; Haggerty K; Lu X; McDonnell JM; Newell DR; Noble ME; Revill CH; Riedinger C; Xu Q; Zhao Y; Lunec J; Hardcastle IR
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5916-9. PubMed ID: 21875801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.
    Zhang L; Ren W; Wang X; Zhang J; Liu J; Zhao L; Zhang X
    Eur J Med Chem; 2017 Jan; 126():1071-1082. PubMed ID: 28027532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
    Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
    J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors.
    Gollner A; Weinstabl H; Fuchs JE; Rudolph D; Garavel G; Hofbauer KS; Karolyi-Oezguer J; Gmaschitz G; Hela W; Kerres N; Grondal E; Werni P; Ramharter J; Broeker J; McConnell DB
    ChemMedChem; 2019 Jan; 14(1):88-93. PubMed ID: 30458062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dispirooxindoles Based on 2-Selenoxo-Imidazolidin-4-Ones: Synthesis, Cytotoxicity and ROS Generation Ability.
    Novotortsev VK; Kukushkin ME; Tafeenko VA; Skvortsov DA; Kalinina MA; Timoshenko RV; Chmelyuk NS; Vasilyeva LA; Tarasevich BN; Gorelkin PV; Erofeev AS; Majouga AG; Zyk NV; Beloglazkina EK
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies.
    Bhatia RK; Singh L; Garg R; Kaur M; Yadav M; Madan J; Kancherla S; Pissurlenkar RRS; Coutinho EC
    Med Chem; 2020; 16(2):212-228. PubMed ID: 31146672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and Biological Evaluation of Novel
    Ivanenkov YA; Kukushkin ME; Beloglazkina AA; Shafikov RR; Barashkin AA; Ayginin AA; Serebryakova MS; Majouga AG; Skvortsov DA; Tafeenko VA; Beloglazkina EK
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents.
    Islam MS; Ghawas HM; El-Senduny FF; Al-Majid AM; Elshaier YAMM; Badria FA; Barakat A
    Bioorg Chem; 2019 Feb; 82():423-430. PubMed ID: 30508794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
    Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
    Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potency and Selectivity Optimization of Tryptophanol-Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer.
    Barcherini V; Almeida J; Lopes EA; Wang M; Magalhães E Silva D; Mori M; Wang S; Saraiva L; Santos MMM
    ChemMedChem; 2021 Jan; 16(1):250-258. PubMed ID: 32737944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
    Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
    J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ligand-Based and Docking-Based Virtual Screening of MDM2 Inhibitors as Potent Anticancer Agents.
    Li BH; Ge JQ; Wang YL; Wang LJ; Zhang Q; Bian C
    Comput Math Methods Med; 2021; 2021():3195957. PubMed ID: 34413896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
    Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
    J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Hybridization-Guided One-Pot Multicomponent Synthesis of Turmerone Motif-Fused 3,3'-Pyrrolidinyl-dispirooxindoles via a 1,3-Dipolar Cycloaddition Reaction.
    Lin B; Zhou G; Gong Y; Wei QD; Tian MY; Liu XL; Feng TT; Zhou Y; Yuan WC
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28420177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction.
    Krasavin M; Gureyev MA; Dar'in D; Bakulina O; Chizhova M; Lepikhina A; Novikova D; Grigoreva T; Ivanov G; Zhumagalieva A; Garabadzhiu AV; Tribulovich VG
    Bioorg Med Chem; 2018 May; 26(9):2651-2673. PubMed ID: 29691156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.
    Shen QK; Deng H; Wang SB; Tian YS; Quan ZS
    Eur J Med Chem; 2019 Jul; 173():15-31. PubMed ID: 30981113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
    Guo Z; Zhuang C; Zhu L; Zhang Y; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Miao Z; Zhang W
    Eur J Med Chem; 2012 Oct; 56():10-6. PubMed ID: 22940704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.